TSRI Study Illuminates How Mystery MS Drug Works
A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera®. The drug is the most widely prescribed pill-based therapy for MS, but its biological mechanism remains mysterious.
Using a new TSRI technology that can quickly reveal a drug’s protein targets, the scientists showed that Tecfidera® interacts with multiple T cell proteins, in some cases inhibiting their activity, and helping to suppress the T cell activation that is a key feature of MS flare-ups.
“This new technology has given us insights into the therapeutic modulation of the immune system that we could not have obtained with standard approaches,” said co-senior author John R. Teijaro, an assistant professor at TSRI.
To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
Washington University/St. Louis Children’s Comprehensive SEEG Course
Aug. 10-12, 2017; St. Louis
Tennessee Neurological Society Annual Meeting
Aug. 11-12, 2017; Nashville, Tenn.